Isentress

Raltegravir

Developed to target human immunodeficiency virus infection to alleviate viral load.

Active ingredient
Raltegravir
Supply
Rx
Route
Oral use
Form
Film-coated tablet
Strengths
400mg

Isentress details

Condition
HIV Infection
Alternative names
Zepdon
Therapeutic class
Integrase Inhibitor
Pharmacological class
HIV-1 Integrase Strand Transfer Inhibitor
Contraindications
hypersensitivity to raltegravir
Minor side effects
headache; nausea; diarrhoea; insomnia
Moderate side effects
abdominal pain; elevated liver enzymes
Dosage forms
Film-coated tablet
Administration route
Oral use
Supply category
Prescription only (specially controlled medicine)
Manufacturer
Merck Sharp & Dohme
Onset Time
1–4 hours
Duration
12 hours
Storage instructions
Store below 30°C in the original packaging.
Drug interactions
Rifampicin; St. John's Wort
Age restrictions
Dosage adjusted based on weight and age.
Precautions and warnings

monitor for symptoms of immune reconstitution syndrome; use with caution in patients with hepatic impairment

Serious side effects

rhabdomyolysis, requires immediate medical attention; severe skin reactions, requires immediate medical attention; myopathy, requires immediate medical attention

Patient summary

developed to target human immunodeficiency virus infection to alleviate viral load.

Mechanism of action

This medicine acts as an integrase strand transfer inhibitor, blocking the enzyme that the virus requires to replicate and integrate its genetic material into the host cell DNA.

Pregnancy and breastfeeding

Pregnancy: use only if potential benefit justifies potential risk. Breastfeeding: breastfeeding is generally not recommended for HIV positive mothers.

Where this medicine is registered

  • Singapore
  • Hong Kong
  • Thailand
  • Malaysia
  • Philippines
  • Indonesia
  • Taiwan
  • South Korea
  • Japan
  • Australia
  • New Zealand
  • UAE
  • South Africa

About Isentress

Isentress is the original formulation of Raltegravir, a medication used in the management of HIV Infection. This active ingredient is also known as Zepdon. Developed by Merck Sharp & Dohme, Isentress is supplied as a 400mg tablet to assist in therapeutic regimens. Access to these standardized options helps maintain consistency in long-term health management for individuals living throughout the region.

Isentress availability in Asia

Isentress is registered across 14 markets, including Singapore, Hong Kong and Thailand, with additional availability in Malaysia, the Philippines and Indonesia. As with many therapies used for chronic conditions, generic Raltegravir produced in centres like India is often more affordable than the original brand. This wider availability supports expats and residents who require reliable access to consistent medication despite distance from a standard supply chain. As with any antiretroviral treatment, this medicine is best used under the ongoing guidance of a qualified doctor to ensure health goals are met appropriately.